New program has benefitted many people with MS across the UK by giving them access to the drugs at affordable prices 

The UK MS Risk-sharing Scheme, devised by the Department of Health (DH), covers four of the disease modifying therapies and these remain the basis for availability of MS drugs at a cost effective price within the NHS across the UK. Since NICE published their original recommendations back in 2002 much work has been going on behind the scenes to improve the analytical methodologies and this paper outlines that work. It is published prior to the results for years 4 and 6 which are due shortly. Nicola Russell director of special projects at the MS Trust said the DH Risk-sharing Scheme has benefitted many people with MS across the UK by giving them access to the drugs at affordable prices on the NHS. In addition it has supported the development of services for all people with MS across the UK. The fact that this Scheme has managed to develop the research methodology is a testament to a lot of hard work by the researchers and ongoing support from the Funders, the DH and four pharmaceutical companies. We look forward to seeing the recommendations from the Scientific Advisory Group on the 4 and 6 year data in due course.
READ MORE